News
November 26, 2021
In a partnership between MSU and Spectrum Health called the Cystic Fibrosis Translational Research program, a team of researchers including MSU biochemist Robert Quinn, is studying the effectiveness of a promising FDA approved treatment called Trikafta that is a combination of the drugs Elexacaftor, Tezacaftor and Ivacaftor. The new treatment is proving to be life-changing for people with cystic fibrosis. The research was published Nov. 24 in the Journal of Cystic Fibrosis.